A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01145989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: AT9283

Sponsor

NCIC Clinical Trials Group

Collaborators

[object Object]